Assesses cytotoxicity and biocompatibility of shrimp-derived chitosan, highlighting its potential benefits.
Exploiting shrimp waste to produce value-added biomaterials brings both environmental and biomedical benefits. In the present work, we propose to extract chitin and to produce chitosan from Parapenaeus longirostris using eco-friendly process . Chitosan was prepared using optimized steps and characterized by FTIR, 1 H NMR, XRD, SEM, EDX, and viscometry. As a preliminary screening step to assess its biocompatibility, different forms of chitosan were cultured with a unicellular strain of paramecia ( Paramecium caudatum ) and other unicellular microorganisms. The results show that chitosan obtained via the Broussignac method, using an autoclave process, exhibits a low degree of acetylation (DA = 9.1%, determined by ¹H NMR), a high molecular weight (222 kDa), a crystallinity of 49.14%, and improved solubility in 0.1% acetic acid. Furthermore, cytotoxicity evaluations demonstrated that shrimp-derived chitosan exhibited higher biocompatibility than commercial chitosan, with an approximately 15% lower mortality rate. It also promoted a significant increase in Paramecium cell density (33%), indicating a stimulatory effect on growth. In contrast, acetic acid showed a strong cytotoxic effect on the culture, inducing a mortality rate of about 80%.Overall, the results are promising and suggest that naturally derived chitosan has strong potential as a non-toxic and sustainable biomaterial, while this simple and ethical unicellular model provides a preliminary, first-line screening platform, to be confirmed through further biological validation prior to in vivo studies in animal models.
No takes yet. Share an insight, caveat, or question.
Armadi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: